Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Advanced or Recurrent Metastatic Gynecologic Tumors (Real-World Study)
ChiCTR2000040335Phase 2Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Nov 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC), endometrial cancer (EC) and 1 more, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Progression-free survival (PFS). Started Nov 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000040335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040335.